Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
Peptides with a sequence length from 13 to 50 amino acids, the N-terminal region of said peptides consisting in the sequence HXaa1EGTFTSDXaa2SXaa3Xaa4 (SEQ ID NO: 1) wherein: Xaa1 is an amino acid selected from alanine and glycine; Xaa2 is an amino acid selected from valine and leucine; Xaa3 is an amino acid selected from serine and lysine; Xaa4 is an amino acid selected from tyrosine and glutamine; and Hystidine is the N-terminal residue; for use in the topical treatment and/or prevention of retinal neurodegenerative diseases, in particular diabetic retinopathy are described. Pharmaceutical topical compositions for use in the topical treatment and/or prevention of these diseases are also described.
1. A method for the treatment of retinal neurodegenerative disease comprising topically administering onto the eye surface a therapeutically effective amount of a peptide with a sequence length from 13 to 50 amino acids, the N-terminal region of said peptide having the sequence:
HXaa 1 EGTFTSDXaa 2 SXaa 3 Xaa 4 (SEQ ID NO: 1) wherein:
Xaa 1 is an amino acid selected from alanine and glycine;
Xaa 2 is an amino acid selected from valine and leucine;
Xaa 3 is an amino acid selected from serine and lysine;
Xaa 4 is an amino acid selected from tyrosine and glutamine; and
hystidine is the N-terminal residue;
together with pharmaceutically acceptable excipients and/or carriers, in a subject in need thereof.
2. The method of claim 1 , wherein the peptide has a sequence length from 30 to 40 amino acids.
3. The method of claim 1 , wherein the retinal neurodegenerative disease is selected from the group consisting of diabetic retinopathy (DR), age-related macular degeneration, glaucoma and retinitis pigmentosa.
4. The method of claim 1 , wherein the retinal neurodegenerative disease is diabetic retinopathy.
5. The method of claim 4 , which is a topical treatment of early stages of the diabetic retinopathy.
6. The method of claim 4 , comprising topically administering onto the eye surface a therapeutically effective amount of a peptide selected from:
(a) the human glucagon-like peptide-1 (7-37) of amino acid sequence SEQ ID NO: 2;
(b) the amino acid sequence SEQ ID NO: 3 (HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG), wherein the lysine residue (K) comprises the lipophilic substituent N ε -(γ-glutamyl(N α -hexadecanoyl)) attached by an amide link to the amino group of the lysine side chain;
(c) the amino acid sequence SEQ ID NO: 4 (HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPXaa 5 ), wherein Xaa 5 is a serine residue in which the —COOH terminal has been replaced by a —NH 2 group; and
(d) the amino acid sequence SEQ ID NO: 8 (HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKXaa 6 ), wherein Xaa 6 is a lysine residue in which the —COOH terminal has been replaced by a —NH 2 group.
7. The method of claim 5 , comprising topically administering onto the eye surface a therapeutically effective amount of a peptide selected from:
(a) the human glucagon-like peptide-1 (7-37) of amino acid sequence SEQ ID NO: 2;
(b) the amino acid sequence SEQ ID NO: 3 (HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG), wherein the lysine residue (K) comprises the lipophilic substituent N ε -(γ-glutamyl(N α -hexadecanoyl)) attached by an amide link to the amino group of the lysine side chain;
(c) the amino acid sequence SEQ ID NO: 4 (HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPXaa 5 ), wherein Xaa 5 is a serine residue in which the —COOH terminal has been replaced by a —NH 2 group; and
(d) the amino acid sequence SEQ ID NO: 8 (HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKXaa 6 ), wherein Xaa 6 is a lysine residue in which the —COOH terminal has been replaced by a —NH 2 group.
8. The method of claim 1 , in which Xaa 1 is alanine, Xaa 2 is valine, Xaa 3 is serine, and Xaa 4 is tyrosine.
9. The method of claim 1 , comprising topically administering onto the eye surface a therapeutically effective amount of a mammal glucagon-like peptide-1.
10. The method of claim 9 , comprising topically administering onto the eye surface a therapeutically effective amount of the human glucagon-like peptide-1 (7-37) of amino acid sequence SEQ ID NO: 2.
11. The method of claim 1 , comprising topically administering onto the eye surface a therapeutically effective amount of the amino acid sequence SEQ ID NO: 3:
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG,
wherein the lysine residue (K) comprises the lipophilic substituent N ε -(γ-glutamyl(N α -hexadecanoyl)) attached by an amide link to the amino group of the lysine side chain.
12. The method of claim 1 , in which Xaa 1 is glycine, Xaa 2 is leucine, Xaa 3 is lysine, and Xaa 4 is glutamine.
13. The method of claim 12 , comprising topically administering onto the eye surface a therapeutically effective amount of the amino acid sequence SEQ ID NO: 4:
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPXaa 5 ,
wherein
Xaa 5 is a serine residue in which the —COOH terminal has been replaced by a —NH 2 group.
14. The method of claim 12 , comprising topically administering onto the eye surface a therapeutically effective amount of the amino acid sequence SEQ ID NO: 8:
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKXaa 6
wherein
Xaa 6 is a lysine residue in which the —COOH terminal has been replaced by a —NH 2 group.
15. The method of claim 1 , wherein the subject is a human.
16. A method for the treatment of a retinal neurodegenerative disease comprising topically administering onto the eye surface a therapeutically effective amount of a pharmaceutical topical composition comprising a peptide with a sequence length from 13 to 50 amino acids, the N-terminal region of said peptide having the sequence:
HXaa 1 EGTFTSDXaa 2 SXaa 3 Xaa 4 (SEQ ID NO: 1) wherein;
Xaa 1 is an amino acid selected from alanine and glycine;
Xaa 2 is an amino acid selected from valine and leucine;
Xaa 3 is an amino acid selected from serine and lysine;
Xaa 4 is an amino acid selected from tyrosine and glutamine; and
hystidine is the N-terminal residue;
together with pharmaceutically acceptable excipients and/or carriers, in a subject in need thereof.
17. The method of claim 16 , wherein the pharmaceutical topical composition is selected from the group consisting of solutions, creams, lotions, unguents, emulsions, and suspensions.
18. The method of claim 16 , wherein the pharmaceutical topical composition is an eye drop solution.
19. The method of claim 16 , wherein the retinal neurodegenerative disease is selected from the group consisting of diabetic retinopathy, age-related macular degeneration, glaucoma and retinitis pigmentosa.
20. The method of claim 16 , wherein the retinal neurodegenerative disease is diabetic retinopathy.
21. The method of claim 16 , wherein the subject is a human.